AZD2693 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metabolic Disorders
Conditions
Metabolic Disorders, Non-alcoholic Steatohepatitis
Trial Timeline
Oct 28, 2019 → Nov 12, 2021
NCT ID
NCT04142424About AZD2693 + Placebo
AZD2693 + Placebo is a phase 1 stage product being developed by AstraZeneca for Metabolic Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT04142424. Target conditions include Metabolic Disorders, Non-alcoholic Steatohepatitis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05107336 | Phase 1 | Completed |
| NCT04142424 | Phase 1 | Completed |
Competing Products
20 competing products in Metabolic Disorders